DE69326637T2 - 1,4-Disubstituierte Piperazine zur Behandlung von Erkrankungen des Zentralnervensystems und von nervenendokrinen Erkrankungen - Google Patents

1,4-Disubstituierte Piperazine zur Behandlung von Erkrankungen des Zentralnervensystems und von nervenendokrinen Erkrankungen

Info

Publication number
DE69326637T2
DE69326637T2 DE69326637T DE69326637T DE69326637T2 DE 69326637 T2 DE69326637 T2 DE 69326637T2 DE 69326637 T DE69326637 T DE 69326637T DE 69326637 T DE69326637 T DE 69326637T DE 69326637 T2 DE69326637 T2 DE 69326637T2
Authority
DE
Germany
Prior art keywords
diseases
treatment
nervous system
central nervous
disubstituted piperazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69326637T
Other languages
English (en)
Other versions
DE69326637D1 (de
Inventor
Jean-Louis Peglion
Bertrand Goument
Mark Millan
Jean-Michel Rivet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Publication of DE69326637D1 publication Critical patent/DE69326637D1/de
Application granted granted Critical
Publication of DE69326637T2 publication Critical patent/DE69326637T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE69326637T 1992-06-12 1993-06-10 1,4-Disubstituierte Piperazine zur Behandlung von Erkrankungen des Zentralnervensystems und von nervenendokrinen Erkrankungen Expired - Fee Related DE69326637T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR929207065A FR2692264B1 (fr) 1992-06-12 1992-06-12 Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.

Publications (2)

Publication Number Publication Date
DE69326637D1 DE69326637D1 (de) 1999-11-11
DE69326637T2 true DE69326637T2 (de) 2000-05-18

Family

ID=9430639

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326637T Expired - Fee Related DE69326637T2 (de) 1992-06-12 1993-06-10 1,4-Disubstituierte Piperazine zur Behandlung von Erkrankungen des Zentralnervensystems und von nervenendokrinen Erkrankungen

Country Status (13)

Country Link
US (1) US5464834A (de)
EP (1) EP0574313B1 (de)
JP (1) JP2634370B2 (de)
AT (1) ATE185345T1 (de)
AU (1) AU658512B2 (de)
CA (1) CA2098252A1 (de)
DE (1) DE69326637T2 (de)
DK (1) DK0574313T3 (de)
ES (1) ES2139638T3 (de)
FR (1) FR2692264B1 (de)
GR (1) GR3031492T3 (de)
NZ (1) NZ247854A (de)
ZA (1) ZA934143B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
FR2734819B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6156057A (en) * 1995-08-12 2000-12-05 Fox; James Allan Method for inducing hypothermia
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
FR2738823B1 (fr) * 1995-09-15 1997-10-31 Synthelabo Derives de 3-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)-3,4-dihydroquinolein-2(1h)-one,leur preparation et leur application en therapeutique
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
US6090132A (en) * 1996-08-15 2000-07-18 Fox; James Allan Method and apparatus for inducing hypothermia
US6436940B2 (en) 1996-12-20 2002-08-20 H. Lundbeck A/S Indane or dihydroindole derivatives
US6331544B1 (en) 1996-12-20 2001-12-18 H. Lundbeck A/S Indane or dihydroindole derivatives
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2128266B1 (es) * 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
AR013206A1 (es) * 1997-07-25 2000-12-13 Lundbeck & Co As H Derivados indol y 2,3-dihidroindol, composiciones farmaceuticas que contienen estos compuestos y el uso de dichos compuestos para la preparacion de un medicamento para el tratamiento de desordenes sensibles a la inhibicion de la reabsorcion de serotonina y antagonismo de receptores 5-ht1a.
CA2297825C (en) * 1997-07-25 2006-03-14 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
TW530054B (en) * 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) * 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6040448A (en) 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
WO1999021850A1 (en) * 1997-10-24 1999-05-06 Neurogen Corporation 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine d4 receptor subtype ligands
US6177566B1 (en) 1998-06-30 2001-01-23 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
DK1113015T3 (da) * 1999-12-29 2004-12-13 Pfizer Prod Inc Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister
ES2188344B1 (es) * 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7371769B2 (en) * 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US20060122177A1 (en) * 2004-12-07 2006-06-08 Solvay Pharmaceuticals B.V. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
DE602005008471D1 (de) * 2004-12-08 2008-09-04 Solvay Pharm Bv Aryloxyethylaminderivate mit einer kombination ausonin-wiederaufnahmehemmung
US20060122247A1 (en) * 2004-12-08 2006-06-08 Solvay Pharmaceuticals B.V. Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
FR2884251B1 (fr) * 2005-04-08 2007-07-13 Servier Lab Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2909670B1 (fr) * 2006-12-12 2010-07-30 Sanofi Aventis Derive fluore de quinoleine-2(1h)-one,son procede de preparation et son utilisation comme intermediaire de synthese
NZ731621A (en) 2009-12-04 2019-01-25 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
IL264446B1 (en) 2016-07-29 2024-05-01 Pgi Drug Discovery Llc Compounds and compositions and their use
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
EP3661929B1 (de) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochromanverbindungen und verwendungen davon
WO2019029802A1 (en) * 2017-08-09 2019-02-14 Telefonaktiebolaget Lm Ericsson (Publ) SYSTEM AND METHOD FOR SELECTING ANTENNA BEAM
WO2019161238A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders
CN113896709B (zh) * 2021-11-22 2023-02-28 南京一苇医药科技有限公司 一种苯并噻吩-3-乙酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037852C3 (de) * 1970-07-30 1980-06-26 Boehringer Sohn Ingelheim Neue Piperazinderivate und Verfahren zu ihrer Herstellung
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2515647A1 (fr) * 1981-11-03 1983-05-06 Cortial Nouvelles imines derivees de (phenyl-4 piperazinylethyl)-2 anilines, leur methode de preparation et leur application therapeutique
EP0185429A1 (de) * 1984-12-21 1986-06-25 Duphar International Research B.V Bizyklische Piperazine
DE3782525T2 (de) * 1986-02-27 1993-05-27 Duphar Int Res Aryl-substituierte(n-piperidinyl)methyl und (n-piperazinyl)methylazole mit antipsychotischer wirkung.
JPH01113377A (ja) * 1987-10-23 1989-05-02 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE4127849A1 (de) * 1991-08-22 1993-02-25 Merck Patent Gmbh Benzodioxanderivate

Also Published As

Publication number Publication date
US5464834A (en) 1995-11-07
DK0574313T3 (da) 2000-04-03
FR2692264B1 (fr) 1994-08-05
ATE185345T1 (de) 1999-10-15
ZA934143B (en) 1994-01-17
ES2139638T3 (es) 2000-02-16
AU4017893A (en) 1993-12-16
DE69326637D1 (de) 1999-11-11
GR3031492T3 (en) 2000-01-31
FR2692264A1 (fr) 1993-12-17
EP0574313A1 (de) 1993-12-15
JP2634370B2 (ja) 1997-07-23
EP0574313B1 (de) 1999-10-06
JPH06179670A (ja) 1994-06-28
CA2098252A1 (fr) 1993-12-13
AU658512B2 (en) 1995-04-13
NZ247854A (en) 1994-09-27

Similar Documents

Publication Publication Date Title
DE69326637D1 (de) 1,4-Disubstituierte Piperazine zur Behandlung von Erkrankungen des Zentralnervensystems und von nervenendokrinen Erkrankungen
ATE125537T1 (de) 1,4-disubstituierte piperazine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE168007T1 (de) Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole
DE59209704D1 (de) 2-Aminomethyl-chromane als Wirkstoffe in Arzneimitteln zur Behandlung von Erkrankungen des Zentralnervensystems
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ZA915727B (en) Quinuclidine derivatives
FI961809A (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
DE69329887D1 (de) Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
ES2165360T3 (es) Cicloalquenos y cicloalcanos 1,3-sustituidos como agentes del sistema nervioso central.
DE69116378D1 (de) Substituierte piperazine als mittel zur behandlung des zentrallen nervensystems
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE3888340T2 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LES LABORATOIRES SERVIER, NEUILLY SUR SEINE, FR

8339 Ceased/non-payment of the annual fee